Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00282308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00282308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2006
Completion date
May 28, 2012
Enrollment
103 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis